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does not add any additional burden to the operative risk
nor does it affect the immediate and early outcome of
these patients. That revascularization alone can amelio-
rate moderate ischaemic mitral regurgitation in most
patients postoperatively. This improvement is translated
into an improvement in the functional class and the
quality of life postoperatively there is no statistical dif-
ference between two groups.Also a procedure to
address the mitral valve in moderate IMR should be
considered in patients with a worse preoperative left
ventricular profile.
http://dx.doi:10.1016/j.jsha.2016.04.034
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Background: Amphetamine is the most commonly used
illicit drug in Saudi Arabia (SA). Frequency and outcome
of Amphetamine-related cardiovascular (CV) complica-
tions in Saudi Arabia have not been previously studied.
Aim: To determine the epidemiological aspects and
clinical outcomes of the cardiovascular complications
among individuals with Amphetamine-Positive Urine
Drug Screening (APUDS) who were admitted to a large
tertiary care facility in Riyadh, SA.
Methods: Retrospective, case-series review of consecu-
tive individuals found to have APUDS and admitted to
King Abdul-Aziz Medical City (KAMC) in Riyadh, SA
between January 2006 through December 2013 inclusive.
Cases with APUDS and concurrent positive cardiac bio-
markers and/or admission to a cardiology unit were
enrolled in the review. Demographic and clinical data
were collected from electronic patient records. All data
variables were managed and analyzed by Microsoft-
Excel and IBM-SPSS software, version 20.
Results: A total of 7450 UDS were performed during the
study period, out of which 720 (9.6%) were positive for
Amphetamine. Forty-two admissions with APUDS were
documented to have CV complications. All cases were
males with a mean age of 41  10 years and predomi-
nantly Saudis. Acute Coronary Syndrome (ACS) was
the most frequent clinical presentation (n = 31, 73.8%),
predominantly of ST Elevation Myocardial Infarction
(STEMI) type. Other less frequent complications include
myoperecarditis and cardiomyopathy. Coronary proce-
dures were performed in 30 cases. Average hospital stay
was 7 days and in-hospital mortality was 7.2%.
Conclusions and Recommendations: ACS is the most fre-
quent CV complication in the Amphetamine users.
Amphetamine-related CV complications tend to occur
at younger age and carry high risk of in-hospital mortal-
ity. UDS should be performed routinely for all indivi-
duals presenting with acute coronary syndrome or
heart failure at young age. Confirmatory test should be
routine available as a standard of care.
http://dx.doi:10.1016/j.jsha.2016.04.035
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35. With full antiplatelet and anticoagulant cover-
age: Still aortic root and left main coronary artery
thrombosis can occur early post left ventricular
assist device implantation
M. alassal
KFMC, Benha, Egypt
We describe a case of 39 years old male underwent
continuous flow LVAD implantation (HeartWare) HVAD
as destination therapy (DT) for severe left ventricular
dysfunction ,moderate right ventricular dysfunction and
severe pulmonary hypertension , presented 3rd day
post-operatively with polymorphic ventricular tachycar-
dia (VT storm) alternating with VF then aborted to brady-
cardia with complete heart block .Coronary angiography
revealed big LM coronary artery thrombus extended dis-
tally to mid LCX and mid LAD arteries and pedunculat-
ing into the aortic root proximally inspite of full coverage
with antiplatelet and anticoagulant therapy. To our
knowledge this is the 1st case documented with this early
presentation post (HeartWare) HVAD device implanta-
tion as destination therapy (DT).We describe a case of
39 years old male underwent continuous flow LVAD
implantation (HeartWare) HVAD as destination therapy
(DT) for severe left ventricular dysfunction, moderate
right ventricular dysfunction and severe pulmonary
hypertension , presented 3rd day post-operatively with
polymorphic ventricular tachycardia (VT storm) alternat-
ing with VF then aborted to bradycardia with complete
heart block . Coronary angiography revealed big LM cor-
onary artery thrombus extended distally to mid LCX and
mid LAD arteries and pedunculating into the aortic root
proximally inspite of full coverage with antiplatelet and
anticoagulant therapy. To our knowledge this is the 1st
case documented with this early presentation post
(HeartWare) HVAD device implantation as destination
therapy (DT). In the modern era, the use of surgically
implanted left ventricular assist devices (LVADs) as a
bridge therapy to either recovery or cardiac transplanta-
tion has given a hope at the end of the HF tunnel. More
recently, the use of LVADs as ‘destination therapy (DT)’
has further illuminated a future for patients with end-
stage HF. To our knowledge this is the 1st case documen-
ted with this early presentation post (HeartWare)HVAD
device implantation as destination therapy (DT).
http://dx.doi:10.1016/j.jsha.2016.04.036
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